ClinicalTrials.gg
CompletedNCT04322305GABI2Updated Nov 18, 2026Results posted

Pregabalin Trial for the Treatment of Alcohol Use Disorder

A Phase 2 interventional study of Pregabalin and Placebo in Alcohol Use Disorder, sponsored by New York State Psychiatric Institute. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-18.

Sponsored by New York State Psychiatric Institute · Phase 2, Interventional, and Treatment

How we know

Updated Nov 18, 2026Now CompletedResults posted+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Alcoholism by New York State Psychiatric Institute — 1 open to participants now, 1 under way, none of them phase 3. Alcoholism · New York State Psychiatric Institute.

Enrollment
6th of 16
43 · median 34
Started
2021
the only one that year
Phase 2
7 of 18
1 open now
Registered
17th of 18
by date

Among the 18 studies in Alcoholism by New York State Psychiatric Institute, this one is the 6th largest by enrollment of the 16 interventional ones that give a count, is the only one that started in 2021, is one of 7 in phase 2, and was the 17th registered.

Alcoholism

1,679 studies on the registry are indexed under Alcoholism; 333 are open to participants now.

Browse Alcoholism studies →

Open to participants now

1 of the 18 studies in Alcoholism by New York State Psychiatric Institute is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Where they have run

Who these studies take

Of the 238 Alcoholism studies recruiting now, 85 (36%) set no upper age limit and 131 (55%) stop at 75 or younger; 9 take children under 18; 64 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Alcoholism by New York State Psychiatric Institute, or all of them as a file.
02

Study summary

In a 10-week randomized double-blind placebo-controlled outpatient pilot trial the efficacy of pregabalin in the treatment of alcohol dependence will be studied in 50 treatment-seeking outpatients. Participants will report drinking a minimum of 5 standard drinks for men or 4 standard drinks for women at least 4 days per week over the past 28 days.

Read the detailed description

In a 10-week double-blind placebo controlled outpatient clinical trial, the safety and efficacy ofpregabalin will be tested in 50 outpatients with Alcohol Use Disorder.Participants will be randomly allocated (1:1) to receive pregabalin or an identical-appearing, inert placebo. All study medication (placebo and pregabalin) will be over-capsulated with riboflavin to assess compliance. Pregabalin will be administered in 75 mg and 100 capsules; placebo capsules will appear identical to the pregabalin capsules. Participants in both study arms will receive the same number of capsules. Pregabalin will be titrated over a 3-week period to the FDA maximum (600 mg per day) or the maximum tolerated dose.

Study visits will occur daily for the first 4 days of the study period, then approximately every other day for the remainder of week 1, for a total of 5 study visits (study days 1,2,3,4, and 5 or 7). During the second week, study visits will continue every other day for a total of 3 study visits (study days 8,10, and 12). During the remainder of the 8-week medication study period, study visits will occur twice weekly. There will be two visits during a post-study taper week (week 9) and a follow-up visit during week 10. One visit per week will be with the research psychiatrist. All participants will have a weekly supportive behavioral treatment session with the research psychiatrist using a manual designed for pharmacotherapy trials in subjects with alcohol use disorders

Due to a federally mandated, institution-wide pause in research activities under our Federal Wide Assurance (FWA) this study was paused on 6/23/2026.

A best interest continuation for participants enrolled when paused was received and the last participant completed on 07/13/2023 IO removed pause on 03/20/2026 Received IRB approval to lift suspension 03/27/2026 NYSPI institutional approval to proceed with research and data analysis was granted on 04/07/2026

03

Conditions studied

  • Alcohol Use Disorder

Browse trials for

Keywords

  • alcohol use disorder
  • treatment
  • pregabalin
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets criteria for current alcohol use disorder
  • Reports drinking a minimum of 5 standard drinks for men or 4 standard drinks for women at least 4 days per week over the past 28 days
  • Between the ages of 18 and 65
  • Able to provide and comply with study procedures

Exclusion criteria

Exclusion Criteria:

  • Subjects with any current psychiatric disorder as defined by , other than Alcohol use disorder, that in the investigator's judgment likely requiring ongoing dosage adjustments of their current medications or requiring changes in their medication and/or might require intervention over the course of the study, including schizophrenia, schizoaffective disorder, psychotic disorders other than transient psychosis due to drug abuse, bipolar disorder, and current suicidality with plan and intent. Individuals who are currently stable on a psychotropic medication for at least 3 months may be included if in the investigator's opinion the psychotropic medication is compatible with the study medication (pregabalin). The medications being allowed are commonly used antidepressants, including the SSRIs (e.g., fluoxetine, paroxetine, fluvoxamine, sertraline, citalopram, escitalopram), SNRI's (e.g., venlafaxine, desvenlafaxine, duloxetine), and bupropion.
  • Evidence of moderate-to-severe alcohol withdrawal Clinical Institute Withdrawal Assessment (revised version) (CIWA-Ar score ≥10)
  • History of alcohol withdrawal seizures or alcohol withdrawal delirium
  • History of allergic reaction to candidate medication (pregabalin)
  • Pregnancy, lactation, or failure in female patients to use adequate methods
  • Unstable physical disorders which might make participation hazardous
  • Subjects who have a current DSM-5 diagnosis of moderate or severe substance use disorder, with the exception of alcohol, nicotine and caffeine dependence. A diagnosis of a mild substance use disorder will not be exclusionary, as long as the current primary substance use disorder is alcohol dependence.
  • Are legally mandated to participate in alcohol use disorder treatment program
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    Pregabalin

    Treatment with pregabalin administered in 75 mg and 100 capsules in dosages up to 600 mg per day for up to 8 weeks (including a 3 week titration run up) followed by a one week taper.

    Drug: Pregabalin

  • Placebo comparator
    Placebo

    Individuals will receive the placebo capsules that appear identical to the pregabalin capsules and will receive the same number of capsules.

    Other: Placebo

Interventions

  • Pregabalin will be provided in 75 and 100 mg capsules twice daily for a maximum dose of 600 mg/day or the maximum tolerated dose over the 8 week medication phase and followed by a one week taper.

    Also known as: Lyrica

  • OtherPlacebo

    Placebo capsules will be provided twice daily over 8 weeks and one week taper..

06

What researchers measure

Primary outcomes

  1. Change in Proportion of Heavy Drinking Days Over Time

    Change in heavy drinking days as quantified by the proportion of heavy drinking (HDD) days (defined as any day where the number of standard drinks was at least 5 for men and at least 4 for women) per week as measured by the timeline follow-back (TLFB) method.

    Time frame: measured weekly over the 8 weeks of the medication phase of the trial or length of each individual's participation

07

Results

Posted Nov 18, 2026

Participant flow

Participant flow — Overall Study
MilestonePregabalinPlacebo
Started2221
Completed1413
Not completed88

Outcome measures

PrimaryChange in Proportion of Heavy Drinking Days Over Time

Change in heavy drinking days as quantified by the proportion of heavy drinking (HDD) days (defined as any day where the number of standard drinks was at least 5 for men and at least 4 for women) per week as measured by the timeline follow-back (TLFB) method.

Time frame:
measured weekly over the 8 weeks of the medication phase of the trial or length of each individual's participation
Reported as:
Least squares mean · percentage of HDD days per week
Change in Proportion of Heavy Drinking Days Over Time
percentage of HDD days per weekPregabalinPlacebo
Week 151.7 (36.2 to 66.9)59.5 (42.2 to 74.7)
Week 837.0 (22.3 to 54.5)46.7 (29.2 to 65.1)
Statistical analysis
  • Pregabalin vs Placebo · Mixed Models Analysis · p = 0.1271 · Mean difference (final values): 0.08604Outcome was analyzed with generalized linear mixed model with a binomial distribution, logit link and AR(1) covariance structure.

Adverse events

Collected over Over the course of the 10 week trial.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pregabalin0/22 (0%)0/22 (0%)21/22 (95.5%)
Placebo0/21 (0%)0/21 (0%)17/21 (81%)
Most frequent other events
Showing 10 of 63
Most frequent other events
EventPregabalinPlacebo
increased blood pressureCardiac disorders11/227/21
tachycardiaCardiac disorders5/222/21
anxietyPsychiatric disorders4/224/21
depressionPsychiatric disorders4/224/21
dizzinessGeneral disorders4/221/21
drowsinessGeneral disorders4/222/21
chest painGeneral disorders0/223/21
dry mouthGeneral disorders3/222/21
fatigueGeneral disorders3/221/21
nauseaGastrointestinal disorders3/221/21

Baseline characteristics

Age, Continuous
Age, Continuous(years)PregabalinPlaceboTotal
Mean44.4 ± 11.648.2 ± 9.746.3 ± 10.8
Sex: Female, Male
Sex: Female, Male(Participants)PregabalinPlaceboTotal
Female6612
Male161531
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PregabalinPlaceboTotal
Hispanic or Latino6612
Not Hispanic or Latino161531
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PregabalinPlaceboTotal
American Indian or Alaska Native101
Asian011
Native Hawaiian or Other Pacific Islander000
Black or African American549
White121224
More than one race235
Unknown or Not Reported213
08

Study locations

1 site
  • Nyspi-Stars
    New York, New York 10019, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results published in this report (after de-identification) (text, tables, figures)

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: beginning 12 months and ending 5 years after article publication

Access criteria: to researcher who provides a methodologically sound proposal to achieve aims in the approved proposal

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2021 to primary completion in Jul 2023, 30 months.

Results were first posted in Nov 2026, 3 years 3 months after primary completion.

Of 123 non-industry phase 2 interventional studies under Alcoholism, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 59. This study's 30 months is below that.

Counting every sponsor, half of 135 studies reached it within 33 months; a quarter within 21 and three quarters within 59.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 18, 2026: primary completion Jun 2025 → Jul 2023 and completion Jun 2025 → Jul 2023.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Mar 24, 2020
First posted
Mar 26, 2020
StartActual
Jan 11, 2021
Primary completionActual
Jul 31, 2023was Jun 2025
CompletionActual
Jul 31, 2023was Jun 2025
Results first posted
Nov 18, 2026
Last update
Nov 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Suspended→Completed Reason for stopping removed
changed Nov 18, 2026
Results
Results posted
posted Nov 18, 2026
Primary completion
Jun 30, 2025→Jul 31, 2023 (actual)
Nov 18, 2026
Study completion
Jun 30, 2025→Jul 31, 2023 (actual)
Nov 18, 2026
Enrollment
50 (estimated)→43 (actual)
Nov 18, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedChange in proportionProportion of heavy drinking daysHeavy Drinking Days Over TimeTime frame: measured weekly over the 8 weeks of the medication phase of the trial or length of each individual's participation
Nov 18, 2026
Documents
Show all 1 update
  1. Nov 18, 2026
    Suspended→Completed
    Why stopped Reason for stopping removed
    Results posted
    Primary completion Jun 30, 2025→Jul 31, 2023 (now actual)
    Study completion Jun 30, 2025→Jul 31, 2023 (now actual)
    Enrollment 50 (estimated)→43 (actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedChange in proportionProportion of heavy drinking daysHeavy Drinking Days Over TimeTime frame: measured weekly over the 8 weeks of the medication phase of the trial or length of each individual's participation
    + 3 other changes: index terms, verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT04322305
Responsible party
John Mariani MD (Research Psychiatrist, New York State Psychiatric Institute) — Principal investigator
First posted
Mar 26, 2020
Start date
Jan 11, 2021
Primary completion
Jul 31, 2023
Completion
Jul 31, 2023
Results posted
Nov 18, 2026
Last update
Nov 18, 2026

Study contacts

john mariani, MD
principal investigator · New York Psychiatric Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pregabalin

Start the discussion